Emerging ALK/ROS1 TKIs for NSCLC

preview_player
Показать описание
David Spigel, MD, and Tony Mok, MD, provide insight on the next generation of ALK/ROS1-targeted agents, brigatinib and lorlatinib, for non–small cell lung cancer.
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Emerging ALK/ROS1 TKIs 0:04:49

Emerging ALK/ROS1 TKIs for NSCLC

Current & Emerging 0:29:51

Current & Emerging Approaches to Acquired Resistance for ALK/ROS1

2023 Best of 0:30:32

2023 Best of Lung: Targeted Therapies in Lung Cancer

New Ideas and 0:31:43

New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

Sequencing Therapy in 0:05:30

Sequencing Therapy in ALK/ROS1-Rearranged NSCLC

The Evolution of 0:04:05

The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

The therapeutic implications 0:22:21

The therapeutic implications of EML4/ALK, ROS-1 and other new biomarkers

Macrocyclic TKIs in 0:28:43

Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors

Best New Lung 0:01:03

Best New Lung Cancer Treatments for ROS1 Mutation

The Evolution of 0:03:31

The Evolution of ALK/ROS1-Targeted TKIs

ROS1-Rearranged NSCLC 0:04:55

ROS1-Rearranged NSCLC

ROS-1 Rearrangements: What 0:01:53

ROS-1 Rearrangements: What Are They?

First and Second 0:22:10

First and Second Generation ALK Inhibitors for the Treatment of Lung Cancer

Upfront Therapy for 0:04:43

Upfront Therapy for ALK/ROS1-Rearranged NSCLC

ALK and ROS1 0:40:53

ALK and ROS1 in Lung Cancer Next Generation Targeted Therapies

EML4/ALK and ROS-1: 0:21:51

EML4/ALK and ROS-1: How do we sequence therapies

Extreme Rare Mutations 0:18:41

Extreme Rare Mutations in Lung Cancer (ROS1, TRK, HER2): Treatment opportunities

Analyzing the Data 0:01:22

Analyzing the Data for Entrectinib in ROS1 TKI-Naive Patients With NSCLC

Pathologic testing for 0:21:08

Pathologic testing for ALK and ROS1 aberrations in NSCLC | Frédérique Penault-Llorca

Second-Line Brigatinib for 0:09:33

Second-Line Brigatinib for ALK/ROS1-Rearranged NSCLC

Future Directions for 0:05:28

Future Directions for ALK+ NSCLC

Dr. Goldman on 0:01:06

Dr. Goldman on Targeted Therapy Options for EGFR-, ALK-, and ROS1-Mutated NSCLC

ROS1 ALK Initial 1:07:25

ROS1 ALK Initial Treatment, Acquired Resistance with Melina Marmarelis, MD and Charu Aggarwal, MD

Upfront treatment of 0:02:37

Upfront treatment of ROS1-rearranged NSCLC